Video
Author(s):
Key opinion leaders take time to review how immune checkpoint inhibitors have transformed outcomes in rectal cancer and non-cutaneous squamous cell cancers and consider how to better structure clinical trial endpoints in CSCC.
IMA203 Displays Efficacy in Heavily Pretreated Melanoma
Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress
Fianlimab/Cemiplimab Demonstrates Persistent Activity in Advanced Melanoma, Independent of LAG-3 and PD-L1 Status
Community Oncologists on the Importance of Self-Reliance and Collegial Trust as Women in Medicine
RP1 Plus Nivolumab Demonstrates Durable Antitumor Activity in Advanced Melanoma
Long-Term KEYNOTE-006 Data Support Pembrolizumab as SOC in Advanced Melanoma
Experts Highlight Noteworthy Research From the 2024 ESMO Congress
MR-Linac Radiotherapy Limits Target Volume, Brain Tissue Exposure in High-Grade Glioma
PFS Data for 177Lu-Dotatate Surpass Clinical Benchmarks in Refractory Meningioma
Nivolumab Plus Radiotherapy Reduces Rates of Biochemical Recurrence in Gleason Grade 5 Prostate Cancer